Therapy News and Research

RSS

FDA approves Abreu BTT 700 System for temperature monitoring

Brain Tunnelgenix Technologies Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance to market its Abreu BTT 700 System for continuous temperature monitoring.

10 Sep 2010

New melanoma drug in the pipeline from Plexxikon and Roche

Researchers from biotech company Plexxikon have found that their candidate drug for skin cancer melanomas can be administered more effectively in early stages of the disease.

9 Sep 2010

3M to acquire Arizant for $810M

3M announced today it has entered into a definitive agreement to acquire Arizant Inc. for a purchase price of $810 million in cash. Based in Eden Prairie, Minn., Arizant is a leading manufacturer of patient warming solutions designed to prevent hypothermia in surgical settings.

9 Sep 2010

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

9 Sep 2010

Total Medical Solutions ranks #291 on 2010 Inc. 500/5000 list of fastest-growing private companies

For the second year, Total Medical Solutions (TMS) has made Inc. magazine's list of the 5,000 fastest-growing private companies in the US. The 2010 Inc. 500/5000 is ranked according to percentage revenue growth when comparing 2006 to 2009. TMS saw its revenue grow by 53 percent and ranks as number 291 in its industry category of Health.

9 Sep 2010

Study results may point way to effective weight loss maintenance

Many people have experienced the frustration that comes with regaining weight that was lost from dieting. According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), the levels of appetite hormones in the body prior to dieting may serve as a predictor of weight regain after dieting.

9 Sep 2010

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

9 Sep 2010

Two genes linked to ovarian clear cell carcinoma

Scientists at the Johns Hopkins Kimmel Cancer Center have identified two genes whose mutations appear to be linked to ovarian clear cell carcinoma, one of the most aggressive forms of ovarian cancer. Clear cell carcinoma is generally resistant to standard therapy.

9 Sep 2010

JHN launches network to advance neuroscience care

Jefferson Hospital for Neuroscience (JHN) is launching the Jefferson Neuroscience Network (JNN) to promote collaboration among area hospitals to advance neuroscience care throughout the region. Chestnut Hill Hospital is the first hospital to join JNN. Through this collaboration, Jefferson and Chestnut Hill will provide the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.

9 Sep 2010

SMA researchers receive grant for Spinal Muscular Atrophy research

Brian Kaspar, PhD, principal investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children's Hospital, along with a team of Spinal Muscular Atrophy (SMA) researchers and clinicians, recently received a $250,000 grant for SMA research and clinic development from Sophia's Cure Foundation via the Pepsi Refresh Project.

9 Sep 2010

Scientists identify molecular marker to analyze chemotherapy response in breast cancer patients

A new predictive marker which could help doctors to decide whether breast cancer patients would benefit from chemotherapy has been identified by a team of scientists. The study, part-funded by Cancer Research UK and published in the British Journal of Cancer today (Wednesday), shows for the first time how this molecular marker has been singled out as an independent factor in examining a breast cancer patient's tumour.

9 Sep 2010

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

A federal appeals court on Tuesday said it will not revisit its decision to uphold settlements that allow pharmaceutical companies to pay competitors to keep generic versions of their drugs off the market, The Wall Street Journal reports. "In April, the U.S. Second Circuit Court of Appeals [in New York] affirmed the legality of a settlement in which Bayer AG, in essence, paid Barr Pharmaceuticals Inc., a potential generic competitor, to drop its patent challenge to Cipro, a Bayer antibiotic."

9 Sep 2010

Scientists discover molecular gatekeeper for arthritis

Elimination of a molecular gatekeeper leads to the development of arthritis in mice, scientists report in a study published in the Journal of Experimental Medicine. The newly discovered gatekeeper is a protein that determines the fate survival or death of damaging cells that mistakenly attack the body's own tissues and lead to autoimmune disorders such as arthritis.

9 Sep 2010

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

9 Sep 2010

Hospitals find new ways to serve growing senior, immigrant, suburban populations

News outlets report on hospital industries in Houston, Texas; Irvine, Calif. and Madison County, La.

9 Sep 2010

Micro-RNAs programmed cells can lead to malignant growth

Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.

9 Sep 2010

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Competitive Technologies, Inc. announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare® Pain Therapy Treatment

9 Sep 2010

NIH awards second $8 million grant for research into health effects of botanical estrogens

An ongoing research initiative into the health effects of botanical estrogens will get an $8 million boost from the National Institutes of Health.

9 Sep 2010

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream. A new study involving 195 infants in South Africa found that children who were treated with PI and then switched to nevirapine were more likely to maintain virus below the detection threshold of the test than infants who continued to receive PI.

9 Sep 2010

Ohio State University receives five-year grant to improve drug therapy using gene profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

9 Sep 2010

Therapy News and Research

FDA approves Abreu BTT 700 System for temperature monitoring

New melanoma drug in the pipeline from Plexxikon and Roche

3M to acquire Arizant for $810M

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Total Medical Solutions ranks #291 on 2010 Inc. 500/5000 list of fastest-growing private companies

Study results may point way to effective weight loss maintenance

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Two genes linked to ovarian clear cell carcinoma

JHN launches network to advance neuroscience care

SMA researchers receive grant for Spinal Muscular Atrophy research

Scientists identify molecular marker to analyze chemotherapy response in breast cancer patients

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

Scientists discover molecular gatekeeper for arthritis

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Hospitals find new ways to serve growing senior, immigrant, suburban populations

Micro-RNAs programmed cells can lead to malignant growth

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

NIH awards second $8 million grant for research into health effects of botanical estrogens

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Ohio State University receives five-year grant to improve drug therapy using gene profiles

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News